MAP2K7 and melanoma: Preclinical studies have shown the efficacy of combining BRAF and MEK inhibitors in melanoma, leading to improved outcomes and a delay in the onset of resistance.287 Clinical trials evaluating the efficacy of combining immune checkpoint inhibitors with targeted therapies are also underway.300